Amedeo Smart

Free Medical Literature Service


 

Amedeo

HIV Infection

  Free Subscription

Articles published in
Antimicrob Agents Chemother
    September 2021
  1. ABDELWAHAB MT, Wasserman S, Brust JCM, Dheda K, et al
    Linezolid population pharmacokinetics in South African adults with drug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2021 Sep 20:AAC0138121. doi: 10.1128/AAC.01381.
    >> Share

  2. ANKROM W, Jackson Rudd D, Schaeffer A, Panebianco D, et al
    Pharmacokinetic and Safety Profile of the Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV.
    Antimicrob Agents Chemother. 2021 Sep 13:AAC0093521. doi: 10.1128/AAC.00935.
    >> Share

  3. CILENTO ME, Reeve AB, Michailidis E, Ilina TV, et al
    Development of Human Immunodeficiency Virus Type 1 Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine (EFdA) Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor Resistant-Strains.
    Antimicrob Agents Chemother. 2021 Sep 13:AAC0116721. doi: 10.1128/AAC.01167.
    >> Share

  4. ZHOU CL, Huang YF, Li YB, Liang TZ, et al
    A new small-molecule compound, Q308, silences latent HIV-1 provirus by suppressing Tat- and FACT-mediated transcription.
    Antimicrob Agents Chemother. 2021 Sep 7:AAC0047021. doi: 10.1128/AAC.00470.
    >> Share

    August 2021
  5. SALAAM-DREYER Z, Streicher EM, Sirgel FA, Menardo F, et al
    Rifampicin mono-resistant tuberculosis is not the same as multidrug-resistant tuberculosis: a descriptive study from Khayelitsha, South Africa.
    Antimicrob Agents Chemother. 2021 Aug 30:AAC0036421. doi: 10.1128/AAC.00364.
    >> Share

  6. NGWALERO P, Brust JCM, van Beek SW, Wasserman S, et al
    Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with rifampin-resistant TB.
    Antimicrob Agents Chemother. 2021 Aug 9:AAC0239920. doi: 10.1128/AAC.02399.
    >> Share

  7. KULARATNE RS, Kufa T, Gumede L, Maseko DV, et al
    Demographic and behavioural risk factors associated with reduced susceptibility of Neisseria gonorrhoeae to first-line antimicrobials in South African men with gonococcal urethral discharge.
    Antimicrob Agents Chemother. 2021 Aug 2:AAC0038921. doi: 10.1128/AAC.00389.
    >> Share

    July 2021
  8. CHIA T, Nakamura T, Amano M, Takamune N, et al
    A small molecule, ACAi-028, with anti-HIV-1 activity targets a novel hydrophobic pocket on HIV-1 capsid.
    Antimicrob Agents Chemother. 2021 Jul 6:AAC0103921. doi: 10.1128/AAC.01039.
    >> Share

    June 2021
  9. KA S, Merindol N, Sow AA, Singh A, et al
    Amaryllidaceae alkaloid cherylline inhibits the replication of dengue and Zika viruses.
    Antimicrob Agents Chemother. 2021 Jun 21:AAC0039821. doi: 10.1128/AAC.00398.
    >> Share

    May 2021
  10. WASSERMAN S, Davis A, Stek C, Chirehwa M, et al
    Plasma pharmacokinetics of high dose oral versus intravenous rifampicin in patients with tuberculous meningitis: a randomized controlled trial.
    Antimicrob Agents Chemother. 2021 May 10. pii: AAC.00140.
    >> Share

  11. NGUYEN NTQ, Gras E, Tran ND, Nguyen NNY, et al
    Pseudomonas aeruginosa Ventilator-Associated Pneumonia Rabbit Model for Preclinical Drug Development.
    Antimicrob Agents Chemother. 2021 May 10. pii: AAC.02724.
    >> Share

    April 2021
  12. MAO Y, Valour F, Nguyen NTQ, Doan TMN, et al
    Multi-mechanistic Monoclonal Antibody Combination Targeting Key Staphylococcus aureus Virulence Determinants in a Rabbit Model of Prosthetic Joint Infection.
    Antimicrob Agents Chemother. 2021 Apr 26. pii: AAC.01832.
    >> Share

  13. SUNDELL J, Wijk M, Bienvenu E, Abelo A, et al
    Factors affecting the pharmacokinetics of pyrazinamide and its metabolites in patients co-infected with HIV - implications for individualized dosing.
    Antimicrob Agents Chemother. 2021 Apr 19. pii: AAC.00046.
    >> Share

    March 2021
  14. SCHOLZ EMB, Mwangi JN, De la Cruz G, Nekorchuk M, et al
    Quantitative Imaging Analysis of the Spatial Relationship between Antiretrovirals, RT-SHIV RNA, and Collagen in the Mesenteric Lymph Nodes of Nonhuman Primates.
    Antimicrob Agents Chemother. 2021 Mar 29. pii: AAC.00019.
    >> Share

  15. PENE DUMITRESCU T, Joshi SR, Xu J, Zhan J, et al
    A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants.
    Antimicrob Agents Chemother. 2021 Mar 22. pii: AAC.02173.
    >> Share

  16. WEI Y, Sluis-Cremer N
    Mutations in the HIV-1 3'-Polypurine Tract and Integrase Strand-Transfer Inhibitor Resistance.
    Antimicrob Agents Chemother. 2021 Mar 15. pii: AAC.02432.
    >> Share

  17. WHITE KL, Osman N, Cuadra-Foy E, Brenner BG, et al
    Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes.
    Antimicrob Agents Chemother. 2021 Mar 1. pii: AAC.02406.
    >> Share

    February 2021
  18. BRUGGEMANS A, Vansant G, Balakrishnan M, Mitchell ML, et al
    GS-9822, a preclinical LEDGIN candidate, displays a block-and-lock phenotype in cell culture.
    Antimicrob Agents Chemother. 2021 Feb 22. pii: AAC.02328.
    >> Share

  19. LODISE TP, Van Wart S, Sund ZM, Bressler AM, et al
    Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN).
    Antimicrob Agents Chemother. 2021;65.
    >> Share

  20. MANDAL S, Prathipati PK, Sunagawa SW, Destache CJ, et al
    A new combination bictegravir+tenofovir alafenamide nanoformulation with prolonged sustained-drug-release potency for HIV-1 PrEP: A concept evaluation study.
    Antimicrob Agents Chemother. 2021 Feb 1. pii: AAC.02320.
    >> Share

    December 2020
  21. FERNANDEZ ML, Marson ME, Mastrantonio GE, Corti MA, et al
    BENZNIDAZOLE IN CEREBROSPINAL FLUID. A CASE SERIES OF CHAGAS DISEASE MENINGOENCEPHALITIS IN HIV POSITIVE PATIENTS.
    Antimicrob Agents Chemother. 2020 Dec 23. pii: AAC.01922.
    >> Share

  22. EKE AC, Shoji K, Best BM, Momper JD, et al
    Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women using Tenofovir Disoproxil Fumarate.
    Antimicrob Agents Chemother. 2020 Dec 14. pii: AAC.02168.
    >> Share

  23. MARGOT N, Ram R, Rhee M, Callebaut C, et al
    Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes.
    Antimicrob Agents Chemother. 2020 Dec 7. pii: AAC.02057.
    >> Share

    November 2020
  24. KANE A, Campbell L, Ky D, Hibbs D, et al
    The antifungal and synergistic effect of bisphosphonates in Cryptococcus.
    Antimicrob Agents Chemother. 2020 Nov 2. pii: AAC.01753.
    >> Share

  25. PHAM CD, Nash E, Liu H, Schmerer MW, et al
    Atypical Mutation in Neisseria gonorrhoeae 23S rRNA Associated with High-Level Azithromycin Resistance.
    Antimicrob Agents Chemother. 2020 Nov 2. pii: AAC.00885.
    >> Share

  26. ZUTZ A, Chen L, Sippl F, Humpe A, et al
    Epigenetic compound screening uncovers small molecules for re-activation of latent HIV-1.
    Antimicrob Agents Chemother. 2020 Nov 2. pii: AAC.01815.
    >> Share

    October 2020
  27. CALCAGNO A, Dal Conte I, Cattaneo D, Testi R, et al
    Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders.
    Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.01902.
    >> Share

  28. WILLBY M, Chopra P, Lemmer D, Klein K, et al
    Molecular evaluation of fluoroquinolone resistance in serial Mycobacterium tuberculosis isolates from individuals diagnosed with multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.01663.
    >> Share

  29. BYRNE JM, Waack U, Weinstein EA, Joshi A, et al
    FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development.
    Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.01983.
    >> Share

  30. WANG X, Mallikaarjun S, Gibiansky E
    Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multi-Drug Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.01202.
    >> Share

  31. BARBEE LA, Soge OO, Ocbamichael N, LeClair A, et al
    A Single-arm Open-label Clinical Trial of 2g Aztreonam for the treatment of N. gonorrhoeae.
    Antimicrob Agents Chemother. 2020 Oct 19. pii: AAC.01739.
    >> Share

  32. ELDESOUKY HE, Salama EA, Lanman NA, Hazbun TR, et al
    Potent synergistic interactions between lopinavir and azole antifungal drugs against emerging multidrug-resistant Candida auris.
    Antimicrob Agents Chemother. 2020 Oct 12. pii: AAC.00684.
    >> Share

  33. BOWMAN ER, Cameron C, Richardson B, Kulkarni M, et al
    In vitro exposure of leukocytes to HIV pre-exposure prophylaxis (PrEP) decreases mitochondrial function and alters gene expression profiles.
    Antimicrob Agents Chemother. 2020 Oct 5. pii: AAC.01755.
    >> Share

  34. HUGHES E, Imperial M, Wallender E, Kajubi R, et al
    Piperaquine exposure is altered by pregnancy, HIV and nutritional status in Ugandan women.
    Antimicrob Agents Chemother. 2020 Oct 5. pii: AAC.01013.
    >> Share

  35. BENAMOR TEIXEIRA ML, Fuller TL, Fragoso da Silveira Gouvea MI, Santos Cruz ML, et al
    Efficacy of Three Antiretroviral Regimens Initiated during Pregnancy: Clinical Experience in Rio de Janeiro.
    Antimicrob Agents Chemother. 2020 Oct 5. pii: AAC.01068.
    >> Share

    August 2020
  36. REICHMUTH ML, Homke R, Zurcher K, Sander P, et al
    Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-naive Patients.
    Antimicrob Agents Chemother. 2020 Aug 31. pii: AAC.00513.
    >> Share

  37. VADDADY P, Kandala B, Yee KL
    Population Pharmacokinetic and Pharmacodynamic Analysis to Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1.
    Antimicrob Agents Chemother. 2020 Aug 31. pii: AAC.00590.
    >> Share

  38. CHIREHWA MT, Court R, De Kock M, Wiesner L, et al
    Population pharmacokinetics of cycloserine, and pharmacokinetic/pharmacodynamic target attainment, in MDR-tuberculosis patients dosed with terizidone.
    Antimicrob Agents Chemother. 2020 Aug 17. pii: AAC.01381.
    >> Share

  39. ADAMOWICZ EM, Harcombe WR
    Weakest link dynamics predict apparent antibiotic interactions in a model cross-feeding community.
    Antimicrob Agents Chemother. 2020 Aug 10. pii: AAC.00465.
    >> Share

  40. FINTELMAN-RODRIGUES N, Sacramento CQ, Ribeiro Lima C, Souza da Silva F, et al
    Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production.
    Antimicrob Agents Chemother. 2020 Aug 5. pii: AAC.00825.
    >> Share

  41. ARQUEZ MA, Martin-Alonso S, Gorelick RJ, Scott WA, et al
    Nucleocapsid protein precursors NCp9 and NCp15 suppress ATP-mediated rescue of AZT-terminated primers by HIV-1 reverse transcriptase.
    Antimicrob Agents Chemother. 2020 Aug 3. pii: AAC.00958.
    >> Share

  42. SKIPPER C, Atukunda M, Stadelman A, Engen N, et al
    Safety and tolerability of a novel oral formulation of amphotericin B: Phase I EnACT Trial.
    Antimicrob Agents Chemother. 2020 Aug 3. pii: AAC.00838.
    >> Share

    July 2020
  43. LOISEAU C, Brites D, Reinhard M, Zurcher K, et al
    HIV coinfection is associated with low fitness rpoB variants in rifampicin-resistant Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2020 Jul 27. pii: AAC.00782.
    >> Share

  44. DEVANATHAN AS, Fallon JK, White NR, Schauer AP, et al
    Antiretroviral penetration and drug transporter concentrations in the spleens of three preclinical animal models and humans.
    Antimicrob Agents Chemother. 2020 Jul 13. pii: AAC.01384.
    >> Share

  45. ZHENG Y, Hirt D, Delma S, Lui G, et al
    Effect of pregnancy on unbound raltegravir concentrations in the ANRS 160 Ralfe trial.
    Antimicrob Agents Chemother. 2020 Jul 13. pii: AAC.00759.
    >> Share

  46. DUMOND JB, Bay CP, Nelson JAE, Davalos A, et al
    Intracellular Tenofovir and Emtricitabine Concentrations in Younger and Older Women with HIV Receiving Tenofovir Disoproxil Fumarate/Emtricitabine.
    Antimicrob Agents Chemother. 2020 Jul 6. pii: AAC.00177.
    >> Share

    June 2020
  47. GEORGI F, Andriasyan V, Witte R, Murer L, et al
    The FDA-approved drug Nelfinavir inhibits lytic cell-free, but not cell-associated non-lytic transmission of human adenovirus.
    Antimicrob Agents Chemother. 2020 Jun 29. pii: AAC.01002.
    >> Share

  48. SMITH SJ, Zhao XZ, Passos DO, Lyumkis D, et al
    HIV-1 Integrase Inhibitors that are active against Drug-Resistant Integrase Mutants.
    Antimicrob Agents Chemother. 2020 Jun 29. pii: AAC.00611.
    >> Share

  49. DE PABLO-BERNAL RS, Jimenez-Leon MR, Tarancon-Diez L, Gutierrez-Valencia A, et al
    Modulation of monocyte activation and function during direct antiviral agents treatment in HIV coinfected patients.
    Antimicrob Agents Chemother. 2020 Jun 22. pii: AAC.00773.
    >> Share

  50. PARSONS TL, Gwenden KN, Marzinke MA
    Inter-species Differences in Tenofovir Alafenamide Fumarate Stability in Plasma.
    Antimicrob Agents Chemother. 2020 Jun 15. pii: AAC.00930.
    >> Share

  51. SORENSEN ES, Macedo AB, Resop RS, Howard JN, et al
    Structure activity relationship analysis of benzotriazine analogues as HIV-1 Latency Reversing Agents.
    Antimicrob Agents Chemother. 2020 Jun 1. pii: AAC.00888.
    >> Share

    May 2020
  52. RAJOLI RKR, Demkovich ZR, Flexner C, Owen A, et al
    Predicting pharmacokinetics of a tenofovir alafenamide subcutaneous implant using PBPK modelling.
    Antimicrob Agents Chemother. 2020 May 18. pii: AAC.00155.
    >> Share

  53. DOUSA KM, Kurz SG, Taracila MA, Bonfield T, et al
    Insights into the L,D-transpeptidases and D,D-carboxypeptidase of Mycobacterium abscessus: ceftaroline, imipenem and novel diazabicyclooctanes inhibitors.
    Antimicrob Agents Chemother. 2020 May 11. pii: AAC.00098.
    >> Share

    March 2020
  54. TYO KM, Lasnik A, Zhang L, Jenson AB, et al
    Rapid-Release Griffithsin Fibers for the Dual Prevention of HSV-2 and HIV-1 Infections.
    Antimicrob Agents Chemother. 2020 Mar 30. pii: AAC.02139.
    >> Share

  55. SEKAGGYA-WILTSHIRE C, Chirehwa M, Musaazi J, von Braun A, et al
    Erratum for Sekaggya-Wiltshire et al., "Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?"
    Antimicrob Agents Chemother. 2020;64.
    >> Share

  56. MARTINEZ MA
    Compounds with therapeutic potential against novel respiratory 2019 coronavirus.
    Antimicrob Agents Chemother. 2020 Mar 9. pii: AAC.00399.
    >> Share

    February 2020
  57. PENG W, Hong Z, Chen X, Gao H, et al
    Thiostrepton reactivates latent HIV-1 through p-TEFb and NF-kappaB pathway mediated by heat shock response.
    Antimicrob Agents Chemother. 2020 Feb 24. pii: AAC.02328.
    >> Share

  58. MCCORMICK KD, Penrose KJ, Brumme CJ, Harrigan R, et al
    Discordance between Etravirine Phenotype and Genotype-based Predicted Phenotype for Subtype C HIV-1 from First-line Antiretroviral Therapy Failures in South Africa.
    Antimicrob Agents Chemother. 2020 Feb 18. pii: AAC.02101.
    >> Share

  59. RABIE H, Tikiso T, Lee J, Fairlie L, et al
    Abacavir exposure in children co-treated for tuberculosis with rifampicin and super-boosted lopinavir-ritonavir.
    Antimicrob Agents Chemother. 2020 Feb 18. pii: AAC.01923.
    >> Share

  60. FRANCIS J, Barnes KI, Workman L, Kredo T, et al
    Drug-drug Interactions between Lumefantrine and Commonly-used Antiretroviral Treatment: An Individual Participant Data Population Pharmacokinetic Meta-Analysis.
    Antimicrob Agents Chemother. 2020 Feb 18. pii: AAC.02394.
    >> Share

  61. ISRAEL S, Elinav H, Elazary R, Porat D, et al
    INCREASED EXPOSURE TO ANTIRETROVIRALS FOLLOWING SLEEVE GASTRECTOMY - A CASE REPORT.
    Antimicrob Agents Chemother. 2020 Feb 3. pii: AAC.02453.
    >> Share

  62. EKE AC, Wang J, Amin K, Shapiro DE, et al
    Fosamprenavir with Ritonavir Pharmacokinetics During Pregnancy.
    Antimicrob Agents Chemother. 2020 Feb 3. pii: AAC.02260.
    >> Share

    January 2020
  63. MARGOT N, Ram R, Abram M, Haubrich R, et al
    Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutations and M184V.
    Antimicrob Agents Chemother. 2020 Jan 27. pii: AAC.02557.
    >> Share

  64. MTHIYANE T, Millard J, Adamson J, Balakrishna Y, et al
    N-acetyltransferase 2 genotypes amongst Zulu Speaking South Africans and isoniazid/N-acetyl-isoniazid pharmacokinetics during anti-tuberculosis treatment.
    Antimicrob Agents Chemother. 2020 Jan 21. pii: AAC.02376.
    >> Share

  65. WASSERMAN S, Huo S, Ky K, Malig YN, et al
    CORRELATION OF LINEZOLID HAIR CONCENTRATIONS WITH PLASMA EXPOSURE IN PATIENTS WITH DRUG-RESISTANT TB.
    Antimicrob Agents Chemother. 2020 Jan 13. pii: AAC.02145.
    >> Share

    December 2019
  66. BJUGARD NYBERG H, Draper HR, Garcia-Prats AJ, Thee S, et al
    Population pharmacokinetics and dosing of ethionamide in children with tuberculosis.
    Antimicrob Agents Chemother. 2019 Dec 23. pii: AAC.01984.
    >> Share

  67. ABDULLAHI ST, Soyinka JO, Olagunju A, Bolarinwa RA, et al
    Differential impact of nevirapine on artemether-lumefantrine pharmacokinetics in individuals stratified by CYP2B6 c.516G>T genotypes.
    Antimicrob Agents Chemother. 2019 Dec 23. pii: AAC.00947.
    >> Share

  68. SU JT, Simpson SM, Sung S, Bryndza Tfaily E, et al
    A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques.
    Antimicrob Agents Chemother. 2019 Dec 23. pii: AAC.01893.
    >> Share

  69. VU TTT, Nguyen NTQ, Tran VG, Gras E, et al
    Protective Efficacy of Monoclonal Antibodies Neutralizing Alpha-Hemolysin and Bicomponent Leukocidins in Rabbit Model of Staphylococcus aureus Necrotizing Pneumonia.
    Antimicrob Agents Chemother. 2019 Dec 16. pii: AAC.02220.
    >> Share

  70. ABDELWAHAB MT, Leisegang R, Dooley KE, Mathad JS, et al
    Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in South African Pregnant Women with Tuberculosis and HIV.
    Antimicrob Agents Chemother. 2019 Dec 16. pii: AAC.01978.
    >> Share

  71. DARCIS G, Maes N, Pasternak AO, Sauvage AS, et al
    Detectability of HIV residual viremia despite therapy is highly associated with treatment with a protease inhibitor-based combination ART.
    Antimicrob Agents Chemother. 2019 Dec 9. pii: AAC.01902.
    >> Share

    November 2019
  72. SRINIVAS N, Cottrell M, Maffuid K, Prince HA, et al
    A Translational Approach to Predicting the Efficacy of Maraviroc-based Regimens as HIV Pre-exposure Prophylaxis.
    Antimicrob Agents Chemother. 2019 Nov 18. pii: AAC.01729.
    >> Share

  73. SUNDELL J, Bienvenu E, Birgersson S, Abelo A, et al
    Population pharmacokinetics and pharmacogenetics of ethambutol in adult patients co-infected with tuberculosis and HIV.
    Antimicrob Agents Chemother. 2019 Nov 11. pii: AAC.01583.
    >> Share

  74. MONOGUE ML, Watson D, Alexander JS, Cavuoti D, et al
    Minimal Cerebrospinal Concentration of Miltefosine Despite Therapeutic Plasma Levels During the Treatment of Amebic Encephalitis.
    Antimicrob Agents Chemother. 2019 Nov 4. pii: AAC.01127.
    >> Share

    October 2019
  75. DLAMINI S, Kuipa M, Enfield K, Skosana S, et al
    Reciprocal modulation of antiretroviral drug and steroid receptor function in vitro.
    Antimicrob Agents Chemother. 2019 Oct 28. pii: AAC.01890.
    >> Share

  76. SALADINI F, Giannini A, Boccuto A, Dragoni F, et al
    Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations.
    Antimicrob Agents Chemother. 2019 Oct 14. pii: AAC.01717.
    >> Share

  77. FISCHER K, Nguyen K, LiWang PJ
    Griffithsin retains anti-HIV-1 potency with changes in gp120 glycosylation and complements broadly neutralizing antibodies PGT121 and PGT126.
    Antimicrob Agents Chemother. 2019 Oct 14. pii: AAC.01084.
    >> Share

  78. DEVANATHAN AS, Pirone JR, Akkina R, Remling-Mulder L, et al
    Antiretroviral penetration across three preclinical animal models and humans in eight putative HIV viral reservoirs.
    Antimicrob Agents Chemother. 2019 Oct 14. pii: AAC.01639.
    >> Share

    September 2019
  79. GREAVES W, Wan H, Yee KL, Kandala B, et al
    Doravirine exposure and HIV-1 suppression after switching from an efavirenz-based regimen to doravirine/lamivudine/tenofovir disoproxil fumarate.
    Antimicrob Agents Chemother. 2019 Sep 23. pii: AAC.01298.
    >> Share

  80. JACOBSSON S, Kularatne R, Kittiyaowamarn R, Maseko V, et al
    High in vitro susceptibility to the first-in-class spiropyrimidinetrione zoliflodacin among consecutive clinical Neisseria gonorrhoeae isolates from Thailand (2018) and South Africa (2015-2017).
    Antimicrob Agents Chemother. 2019 Sep 23. pii: AAC.01479.
    >> Share

  81. BEKERMAN E, Hesselgesser J, Carr B, Nagel M, et al
    PD-1 blockade and TLR7 activation lack therapeutic benefit in chronic SIV-infected macaques on antiretroviral therapy.
    Antimicrob Agents Chemother. 2019 Sep 9. pii: AAC.01163.
    >> Share

  82. MARTINEC O, Huliciak M, Staud F, Cecka F, et al
    Anti-HIV and anti-HCV drugs inhibit p-glycoprotein efflux activity in Caco-2 cells and precision-cut rat and human intestinal slices.
    Antimicrob Agents Chemother. 2019 Sep 3. pii: AAC.00910.
    >> Share

    August 2019
  83. WANG Q, Modongo C, Allender C, Engelthaler DM, et al
    Utility of targeted, amplicon-based deep sequencing to detect resistance to first-line tuberculosis drugs in Botswana.
    Antimicrob Agents Chemother. 2019 Aug 12. pii: AAC.00982.
    >> Share

  84. SALINGER DH, Subramoney V, Everitt D, Nedelman JR, et al
    Population Pharmacokinetics of Pretomanid.
    Antimicrob Agents Chemother. 2019 Aug 12. pii: AAC.00907.
    >> Share

    July 2019
  85. ENIMIL A, Antwi S, Yang H, Dompreh A, et al
    Effect of first-line antituberculosis therapy on nevirapine pharmacokinetics in children younger than 3 years old.
    Antimicrob Agents Chemother. 2019 Jul 22. pii: AAC.00839.
    >> Share

    June 2019
  86. MALLAYASAMY S, Chaturvedula A, Fossler MJ, Sale M, et al
    Tenofovir plasma concentration from pre-exposure prophylaxis (PrEP) at the time of potential HIV exposure: a population pharmacokinetic modeling and simulation study involving serodiscordant couples in East Africa.
    Antimicrob Agents Chemother. 2019 Jun 10. pii: AAC.00446.
    >> Share

  87. LE HN, Tran VG, Vu TTT, Gras E, et al
    Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa blood stream infection and acute pneumonia rabbit models.
    Antimicrob Agents Chemother. 2019 Jun 3. pii: AAC.00710.
    >> Share

  88. BARNARD JP, Huber KD, Sluis-Cremer N
    NNRTI Hyper-Susceptibility and Resistance: Mutational Analysis of Residue 181 in HIV-1 Reverse Transcriptase.
    Antimicrob Agents Chemother. 2019 Jun 3. pii: AAC.00676.
    >> Share

  89. ZENG Q, Bai M, Li C, Lu S, et al
    Multiple drug transporters contribute to the placental transfer of emtricitabine.
    Antimicrob Agents Chemother. 2019 Jun 3. pii: AAC.00199.
    >> Share

    May 2019
  90. THEYS K, Libin PJK, Van Laethem K, Abecasis AB, et al
    An evolutionary-based approach to quantify the genetic barrier to drug resistance in fast-evolving viruses: an application to HIV-1 subtypes and integrase inhibitors.
    Antimicrob Agents Chemother. 2019 May 20. pii: AAC.00539.
    >> Share

  91. SUVICHAPANICH S, Wattanapokayakit S, Mushiroda T, Yanai H, et al
    Genome-Wide Association Study Confirming the Association of NAT2 with Susceptibility to Anti-tuberculosis Drug-Induced Liver Injury in Thai Patients.
    Antimicrob Agents Chemother. 2019 May 20. pii: AAC.02692.
    >> Share

  92. TAKAMATSU Y, Aoki M, Bulut H, Das D, et al
    Novel protease inhibitors containing C-5-modified bis-THF and aminobenzothiazole as P2 and P2' ligands that exert potent antiviral activity against highly multidrug-resistant HIV-1 with high genetic barrier against the emergence of drug resistance.
    Antimicrob Agents Chemother. 2019 May 13. pii: AAC.00372.
    >> Share

  93. AMANO M, Salcedo-Gomez PM, Yedidi RS, Zhao R, et al
    Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.
    Antimicrob Agents Chemother. 2019 May 6. pii: AAC.00466.
    >> Share

    April 2019
  94. HATTORI SI, Hayashi H, Bulut H, Rao KV, et al
    Halogen bond interactions of novel HIV-1 protease inhibitors (PI)(GRL-001-15 and GRL-003-15) with the flap of protease are critical for their potent activity against wild-type and multi-PI-resistant HIV-1 variants.
    Antimicrob Agents Chemother. 2019 Apr 8. pii: AAC.02635.
    >> Share

    March 2019
  95. SEKAGGYA-WILTSHIRE C, Chirehwa M, Musaazi J, von Braun A, et al
    Low anti-tuberculosis drug concentrations in HIV-Tuberculosis co-infected adults with low body weight; is it time to update dosing guidelines?
    Antimicrob Agents Chemother. 2019 Mar 25. pii: AAC.02174.
    >> Share

  96. BECCARI MV, Mogle BT, Sidman EF, Mastro KA, et al
    Ibalizumab: A novel monoclonal antibody for the management of multidrug resistant HIV-1 infection.
    Antimicrob Agents Chemother. 2019 Mar 18. pii: AAC.00110.
    >> Share

    February 2019
  97. SMITH RA, Raugi DN, Wu VH, Zavala CG, et al
    Comparison of the Antiviral Activity of Bictegravir Against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants.
    Antimicrob Agents Chemother. 2019 Feb 25. pii: AAC.00014.
    >> Share

  98. ACOSTA RK, Willkom M, Martin R, Chang S, et al
    Resistance Analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients Through 48 Weeks.
    Antimicrob Agents Chemother. 2019 Feb 25. pii: AAC.02533.
    >> Share

  99. KHALILIEH SG, Yee KL, Sanchez RI, Fan L, et al
    Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions.
    Antimicrob Agents Chemother. 2019 Feb 19. pii: AAC.02016.
    >> Share

  100. ANKROM W, Sanchez RI, Yee KL, Fan L, et al
    Investigation of Pharmacokinetic Interactions Between Doravirine and Elbasvir/Grazoprevir and Ledipasvir/Sofosbuvir.
    Antimicrob Agents Chemother. 2019 Feb 19. pii: AAC.02491.
    >> Share

  101. BLEASBY K, Fillgrove KL, Houle R, Lu B, et al
    In Vitro Evaluation of the Drug Interaction Potential of Doravirine.
    Antimicrob Agents Chemother. 2019 Feb 11. pii: AAC.02492.
    >> Share

  102. YEE KL, Ouerdani A, Claussen A, de Greef R, et al
    Population Pharmacokinetics of Doravirine and Exposure-Response in Individuals with HIV-1.
    Antimicrob Agents Chemother. 2019 Feb 11. pii: AAC.02502.
    >> Share

  103. FENG HP, Caro L, Fandozzi C, Chu X, et al
    Pharmacokinetic Interactions Between the HCV Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, or Darunavir in Healthy Participants.
    Antimicrob Agents Chemother. 2019 Feb 11. pii: AAC.02142.
    >> Share

  104. BUCKNER FS, Ranade RM, Gillespie JR, Shibata S, et al
    Optimization of methionyl tRNA-synthetase inhibitors for treatment of Cryptosporidium infection.
    Antimicrob Agents Chemother. 2019 Feb 11. pii: AAC.02061.
    >> Share

  105. GYGLI SM, Keller PM, Ballif M, Blochliger N, et al
    Whole genome sequencing for drug resistance profile prediction in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2019 Feb 4. pii: AAC.02175.
    >> Share

    January 2019
  106. FRANCIS J, Zvada SP, Denti P, Hatherill M, et al
    Arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of Rifapentine: a population pharmacokinetics analysis.
    Antimicrob Agents Chemother. 2019 Jan 22. pii: AAC.01964.
    >> Share

  107. HIGASHI-KUWATA N, Hayashi S, Das D, Kohgo S, et al
    CMCdG, a novel nucleoside analog, exerts potent activity against wild-type and entecavir-resistant HBV with favorable safety feature.
    Antimicrob Agents Chemother. 2019 Jan 22. pii: AAC.02143.
    >> Share

  108. BEDNASZ CJ, Venuto CS, Ma Q, Daar ES, et al
    Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202.
    Antimicrob Agents Chemother. 2019 Jan 14. pii: AAC.01638.
    >> Share

  109. WASSERMAN S, Denti P, Brust JCM, Tareq M, et al
    Linezolid pharmacokinetics in South African patients with drug resistant tuberculosis and a high prevalence of HIV co-infection.
    Antimicrob Agents Chemother. 2019 Jan 7. pii: AAC.02164.
    >> Share

  110. YOSHINAGA T, Miki S, Kawauchi-Miki S, Seki T, et al
    Barrier to resistance of dolutegravir in two-drug combinations.
    Antimicrob Agents Chemother. 2019 Jan 2. pii: AAC.02104.
    >> Share

  111. NOGUCHI LM, Hoesley C, Kelly C, Scheckter R, et al
    Pharmacokinetics of Dapivirine Transfer into Blood Plasma, Breast Milk, and Cervicovaginal Fluid of Lactating Women using the Dapivirine Vaginal Ring.
    Antimicrob Agents Chemother. 2019 Jan 2. pii: AAC.01930.
    >> Share

    November 2018
  112. VARGAS B, Giacobbi NS, Sanyal A, Venkatachari NJ, et al
    Inhibitors of Signaling Pathways that Block Reversal of HIV-1 Latency.
    Antimicrob Agents Chemother. 2018 Nov 19. pii: AAC.01744.
    >> Share

  113. MEIKLE V, Mossberg AK, Mitra A, Hakansson AP, et al
    A protein complex from human milk enhances the activity of antibiotics and drugs against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2018 Nov 12. pii: AAC.01846.
    >> Share

  114. WALIMBWA SI, Lamorde M, Waitt C, Kaboggoza J, et al
    DRUG INTERACTIONS BETWEEN DOLUTEGRAVIR AND ARTEMETHER-LUMEFANTRINE OR ARTESUNATE-AMODIAQUINE.
    Antimicrob Agents Chemother. 2018 Nov 12. pii: AAC.01310.
    >> Share

  115. KWARA A, Yang H, Antwi S, Enimil A, et al
    Effect of rifampin/isoniazid-containing antituberculosis therapy on efavirenz pharmacokinetics in HIV-infected children aged 3 to 14 years old.
    Antimicrob Agents Chemother. 2018 Nov 5. pii: AAC.01657.
    >> Share

    October 2018
  116. HU Y, Liu Y, Coates A
    Azidothymidine produces synergistic activity in combination with colistin against antibiotic-resistant Enterobacteriaceae.
    Antimicrob Agents Chemother. 2018 Oct 29. pii: AAC.01630.
    >> Share

  117. LIN H, Stankov MV, Hegermann J, Budida R, et al
    Zidovudine-mediated autophagy inhibition enhances mitochondrial toxicity in muscle cells.
    Antimicrob Agents Chemother. 2018 Oct 29. pii: AAC.01443.
    >> Share

  118. CRESSEY TR, Harrison L, Achalapong J, Kanjanavikai P, et al
    Tenofovir exposure during pregnancy and postpartum in women receiving tenofovir disoproxil fumarate for the prevention of mother-to-child transmission of hepatitis B virus.
    Antimicrob Agents Chemother. 2018 Oct 1. pii: AAC.01686.
    >> Share

    September 2018
  119. DIAN S, Yunivita V, Ganiem AR, Pramaesya T, et al
    A double-blinded randomised placebo-controlled phase II trial to evaluate high dose rifampicin for tuberculous meningitis: a dose finding study.
    Antimicrob Agents Chemother. 2018 Sep 17. pii: AAC.01014.
    >> Share

  120. GOMES A, Ferraz R, Ficker L, Collins MS, et al
    Chloroquine analogues as leads against Pneumocystis lung pathogens.
    Antimicrob Agents Chemother. 2018 Sep 10. pii: AAC.00983.
    >> Share

    August 2018
  121. BANDA CG, Dzinjalamala F, Mukaka M, Mallewa J, et al
    Impact of efavirenz, ritonavir-boosted lopinavir and nevirapine based antiretroviral regimens on the pharmacokinetics of lumefantrine and safety of artemether-lumefantrine in falciparum-negative HIV-infected Malawian adults stabilized on antiretrovira
    Antimicrob Agents Chemother. 2018 Aug 27. pii: AAC.01162.
    >> Share

  122. SPIVAK AM, Nell RA, Petersen M, Martins L, et al
    Synthetic Ingenols Maximize Protein Kinase C-Induced HIV-1 Latency Reversal.
    Antimicrob Agents Chemother. 2018 Aug 13. pii: AAC.01361.
    >> Share

  123. INNES S, van der Laan L, Anderson PL, Cotton M, et al
    CAN WE IMPROVE STAVUDINE'S SAFETY PROFILE IN CHILDREN? PHARMACOKINETICS OF INTRACELLULAR STAVUDINE-TRIPHOSPHATE WITH REDUCED-DOSING.
    Antimicrob Agents Chemother. 2018 Aug 13. pii: AAC.00761.
    >> Share

  124. KANDLER JL, Mercante AD, Dalton TL, Ezewudo MN, et al
    Validation of novel Mycobacterium tuberculosis isoniazid resistance mutations not detectable by common molecular tests.
    Antimicrob Agents Chemother. 2018 Aug 6. pii: AAC.00974.
    >> Share

  125. ADEGBOLA A, Abutaima R, Olagunju A, Ijarotimi O, et al
    Effect of pregnancy on the pharmacokinetic interaction between efavirenz and lumefantrine in HIV-malaria co-infection.
    Antimicrob Agents Chemother. 2018 Aug 6. pii: AAC.01252.
    >> Share

  126. DOOKIE N, Naidoo K, Padayatchi N
    Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2018;62.
    >> Share

    July 2018
  127. MILLER JT, Zhao H, Masaoka T, Varnado B, et al
    Sensitivity of the C-terminal nuclease domain of Kaposi's sarcoma-associated herpesvirus ORF29 to two classes of active site ligands.
    Antimicrob Agents Chemother. 2018 Jul 30. pii: AAC.00233.
    >> Share

  128. SMITH RA, Wu VH, Zavala CG, Raugi DN, et al
    In vitro antiviral activity of cabotegravir against HIV-2.
    Antimicrob Agents Chemother. 2018 Jul 16. pii: AAC.01299.
    >> Share

  129. BARRETT SE, Teller RS, Forster SP, Li L, et al
    Extended Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention.
    Antimicrob Agents Chemother. 2018 Jul 16. pii: AAC.01058.
    >> Share

  130. KANWAR A, Cadnum JL, Jencson AL, Donskey CJ, et al
    Impact of Antibiotic Treatment on the Burden of Nasal Staphylococcus aureus Among Hospitalized Patients.
    Antimicrob Agents Chemother. 2018 Jul 16. pii: AAC.00609.
    >> Share

  131. SMITH SJ, Zhao XZ, Burke TR Jr, Hughes SH, et al
    HIV-1 integrase inhibitors that are broadly effective against drug-resistant mutants.
    Antimicrob Agents Chemother. 2018 Jul 9. pii: AAC.01035.
    >> Share

  132. MEHTA R, Wolstenholme A, Di Lullo K, Fu C, et al
    Bioequivalence of a Fixed-Dose Combination Tablet of the Complete 2-Drug Regimen Dolutegravir and Rilpivirine for the Treatment of HIV-1 Infection.
    Antimicrob Agents Chemother. 2018 Jul 9. pii: AAC.00748.
    >> Share

    June 2018
  133. ANKROM W, Yee KL, Sanchez RI, Adedoyin A, et al
    Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics.
    Antimicrob Agents Chemother. 2018 Jun 11. pii: AAC.00326.
    >> Share

    May 2018
  134. SPADARI CC, Vila T, Rozental S, Ishida K, et al
    Miltefosine has post-antifungal effect and induces apoptosis in Cryptococcus yeasts.
    Antimicrob Agents Chemother. 2018 May 29. pii: AAC.00312.
    >> Share

  135. BANDA CG, Dzinjalamala F, Mukaka M, Mallewa J, et al
    Pharmacokinetics of piperaquine and safety profile of dihydroartemisinin-piperaquine co-administered with antiretroviral therapy in malaria-uninfected HIV-positive Malawian adults.
    Antimicrob Agents Chemother. 2018 May 21. pii: AAC.00634.
    >> Share

  136. YEW WW, Chang KC, Chan DP
    Oxidative Stress and First-Line Antituberculosis Drug-Induced Hepatotoxicity.
    Antimicrob Agents Chemother. 2018 May 21. pii: AAC.02637.
    >> Share

  137. BANDA CG, Dzinjalamala F, Mukaka M, Mallewa J, et al
    Pharmacokinetics and safety profile of artesunate-amodiaquine co-administered with antiretroviral therapy in malaria uninfected HIV-positive Malawian adults.
    Antimicrob Agents Chemother. 2018 May 14. pii: AAC.00412.
    >> Share

  138. FOCA E, Calcagno A, Bonito A, Cusato J, et al
    Pharmacokinetic Changes during Pregnancy According to Genetic Variants: A Prospective Study in HIV-infected Patients Receiving Atazanavir/Ritonavir.
    Antimicrob Agents Chemother. 2018 May 14. pii: AAC.00309.
    >> Share

  139. AMMERMAN NC, Swanson RV, Bautista EM, Almeida DV, et al
    Impact of Clofazimine Dosing on Treatment-Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.
    Antimicrob Agents Chemother. 2018 May 7. pii: AAC.00636.
    >> Share

    April 2018
  140. STADER F, Kinvig H, Battegay M, Khoo S, et al
    Analysis of clinical drug-drug interaction data to predict uncharacterized interaction magnitudes between antiretroviral drugs and co-medications.
    Antimicrob Agents Chemother. 2018 Apr 23. pii: AAC.00717.
    >> Share

  141. MOURE R, Domingo P, Villarroya J, Gasa L, et al
    Reciprocal effects of antiretroviral drugs used to treat HIV infection on the fibroblast growth factor-21/beta-Klotho system.
    Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.00029.
    >> Share

    March 2018
  142. ENOSI TUIPULOTU D, Netzler NE, Lun JH, Mackenzie JM, et al
    TLR7 agonists display potent antiviral effects against norovirus infection via innate stimulation.
    Antimicrob Agents Chemother. 2018 Mar 12. pii: AAC.02417.
    >> Share

    February 2018
  143. LE HN, Quetz JS, Tran VG, Le VTM, et al
    MEDI3902 correlates of protection against severe Pseudomonas aeruginosa pneumonia in a rabbit acute pneumonia model.
    Antimicrob Agents Chemother. 2018 Feb 26. pii: AAC.02565.
    >> Share

  144. DELINO NS, Aoki M, Hayashi H, Hattori SI, et al
    GRL-079, a novel P2-Tp-THF-C5-alkylamine- and P2' -Abt-containing HIV-1 protease inhibitor, is extremely potent against multi-drug-resistant HIV-1 variants including HIVDRV(R)p51 and has a high genetic barrier against the emergence of resistant varian
    Antimicrob Agents Chemother. 2018 Feb 20. pii: AAC.02060.
    >> Share

    January 2018
  145. UCHIYA KI, Asahi S, Futamura K, Hamaura H, et al
    Antibiotic susceptibility and genotyping of Mycobacterium avium strains that cause pulmonary and disseminated infection.
    Antimicrob Agents Chemother. 2018 Jan 29. pii: AAC.02035.
    >> Share

    November 2017
  146. KAKADIYA PP, Higginson RT, Fulco PP
    Ritonavir-boosted protease inhibitors but not cobicistat appear safe in HIV-positive patients ingesting dabigatran.
    Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.02275.
    >> Share

  147. DENTI P, Garcia-Prats AJ, Draper HR, Wiesner L, et al
    Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.01521.
    >> Share

  148. VAN DER LAAN LE, Garcia-Prats AJ, Schaaf HS, Tikiso T, et al
    Pharmacokinetics and drug-drug interactions of lopinavir/ritonavir administered with first and second-line antituberculosis drugs in HIV-infected children treated for multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.00420.
    >> Share

    October 2017
  149. XIAO P, Gumber S, Marzinke MA, Date AA, et al
    Hypo-osmolar formulation of TFV enema promotes uptake and metabolism of TFV in tissues and leading to prevention of SHIV/SIV infection.
    Antimicrob Agents Chemother. 2017 Oct 30. pii: AAC.01644.
    >> Share

  150. HERRERO-FERNANDEZ I, Pacheco YM, Genebat M, Rodriguez-Mendez MDM, et al
    Association between a suppressor combined antiretroviral therapy containing Maraviroc and the hepatitis B virus vaccine response.
    Antimicrob Agents Chemother. 2017 Oct 30. pii: AAC.02050.
    >> Share

  151. HEALAN AM, Griffiss JM, Proskin HM, O'Riordan MA, et al
    Impact of Rifabutin or Rifampin on Bedaquiline Safety, Tolerability, and Pharmacokinetics: A Randomized Clinical Trial in Healthy Adult Volunteers.
    Antimicrob Agents Chemother. 2017 Oct 23. pii: AAC.00855.
    >> Share

  152. ANDERSON PL, Liu AY, Castillo-Mancilla JR, Gardner EM, et al
    Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy: the DOT-DBS Study.
    Antimicrob Agents Chemother. 2017 Oct 16. pii: AAC.01710.
    >> Share

  153. SERRANO-VILLAR S, Caruana G, Zlotnik A, Perez-Molina JA, et al
    The effects of maraviroc versus efavirenz in combination with zidovudine/lamivudine on the CD4/CD8 ratio in treatment-naive HIV-infected individuals.
    Antimicrob Agents Chemother. 2017 Oct 9. pii: AAC.01763.
    >> Share

    September 2017
  154. ELOY P, Tessier A, Fan-Havard P, Chou M, et al
    Genetics of nevirapine metabolic pathways at steady state in HIV-infected Cambodians.
    Antimicrob Agents Chemother. 2017 Sep 25. pii: AAC.00733.
    >> Share

  155. HASSOUNAH SA, Alikhani A, Oliveira M, Bharaj S, et al
    Antiviral Activity of Bictegravir and Cabotegravir Against Integrase Inhibitor Resistant SIVmac239 and HIV-1.
    Antimicrob Agents Chemother. 2017 Sep 18. pii: AAC.01695.
    >> Share

  156. PATEL S, Leibrand CR, Palasuberniam P, Couraud PO, et al
    Effects of HIV-1 Tat and Methamphetamine on Blood-Brain Barrier Integrity and Function In Vitro.
    Antimicrob Agents Chemother. 2017 Sep 11. pii: AAC.01307.
    >> Share

  157. ZHAO N, Wang G, Das AT, Berkhout B, et al
    Combinatorial CRISPR-Cas9 and RNAi attack on HIV-1 DNA and RNA can lead to cross-resistance.
    Antimicrob Agents Chemother. 2017 Sep 11. pii: AAC.01486.
    >> Share

  158. KOSAKA M, Ushiki A, Ikuyama Y, Hirai K, et al
    Efficacy and toxicity of low-dose trimethoprim-sulfamethoxazole for the treatment of pneumocystis pneumonia in patients without human immunodeficiency virus infection: A four-center retrospective study.
    Antimicrob Agents Chemother. 2017 Sep 11. pii: AAC.01173.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016